These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 24728334)

  • 1. Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients.
    Sorensen PS; Koch-Henriksen N; Petersen T; Ravnborg M; Oturai A; Sellebjerg F
    J Neurol; 2014 Jun; 261(6):1170-7. PubMed ID: 24728334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab.
    Rossi S; Motta C; Studer V; De Chiara V; Barbieri F; Monteleone F; Fornasiero A; Coarelli G; Bernardi G; Cutter G; Stüve O; Salvetti M; Centonze D
    Eur J Neurol; 2013 Jan; 20(1):87-94. PubMed ID: 22741530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple Sclerosis Disease Activity and Disability Following Discontinuation of Natalizumab for Pregnancy.
    Hellwig K; Tokic M; Thiel S; Esters N; Spicher C; Timmesfeld N; Ciplea AI; Gold R; Langer-Gould A
    JAMA Netw Open; 2022 Jan; 5(1):e2144750. PubMed ID: 35072719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
    Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008933. PubMed ID: 23744561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for reactivation of clinical disease activity in multiple sclerosis after natalizumab cessation.
    Mustonen T; Rauma I; Hartikainen P; Krüger J; Niiranen M; Selander T; Simula S; Remes AM; Kuusisto H
    Mult Scler Relat Disord; 2020 Feb; 38():101498. PubMed ID: 31864192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis.
    Gueguen A; Roux P; Deschamps R; Moulignier A; Bensa C; Savatovsky J; Heran F; Gout O
    J Neurol Neurosurg Psychiatry; 2014 Sep; 85(9):1038-40. PubMed ID: 24876183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis.
    Havla J; Tackenberg B; Hellwig K; Meinl I; Krumbholz M; Seitz F; Eienbröker C; Gold R; Hohlfeld R; Kleiter I; Kümpfel T
    J Neurol; 2013 May; 260(5):1382-7. PubMed ID: 23266894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy.
    Stüve O; Cravens PD; Frohman EM; Phillips JT; Remington GM; von Geldern G; Cepok S; Singh MP; Tervaert JW; De Baets M; MacManus D; Miller DH; Radü EW; Cameron EM; Monson NL; Zhang S; Kim R; Hemmer B; Racke MK
    Neurology; 2009 Feb; 72(5):396-401. PubMed ID: 18987352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulatory drugs (natalizumab), worsening of multiple sclerosis, rebound effect and similitude.
    Teixeira MZ
    Homeopathy; 2013 Jul; 102(3):215-24. PubMed ID: 23870382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N; Lahoz R; Reynolds T; Korn JR
    Curr Med Res Opin; 2014 Aug; 30(8):1461-71. PubMed ID: 24754349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What to expect after natalizumab cessation in a real-life setting.
    Salhofer-Polanyi S; Baumgartner A; Kraus J; Maida E; Schmied M; Leutmezer F
    Acta Neurol Scand; 2014 Aug; 130(2):97-102. PubMed ID: 24720783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY).
    Cohan SL; Moses H; Calkwood J; Tornatore C; LaGanke C; Smoot KE; Meka V; Okwuokenye M; Hotermans C; Mendoza JP; Mann MK; Meltzer LA
    Mult Scler Relat Disord; 2018 May; 22():27-34. PubMed ID: 29524759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation.
    Weinstock-Guttman B; Hagemeier J; Kavak KS; Saini V; Patrick K; Ramasamy DP; Nadeem M; Carl E; Hojnacki D; Zivadinov R
    J Neurol Neurosurg Psychiatry; 2016 Sep; 87(9):937-43. PubMed ID: 26780938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natalizumab therapy for highly active pediatric multiple sclerosis.
    Kornek B; Aboul-Enein F; Rostasy K; Milos RI; Steiner I; Penzien J; Hellwig K; Pitarokoili K; Storm van's Gravesande K; Karenfort M; Blaschek A; Meyer A; Seidl R; Debelic D; Vass K; Prayer D; Kristoferitsch W; Bayas A
    JAMA Neurol; 2013 Apr; 70(4):469-75. PubMed ID: 23420110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroborreliosis during natalizumab treatment in multiple sclerosis.
    Thomas K; Schultheiss T; Ziemssen T
    Neurology; 2013 Sep; 81(11):1012-4. PubMed ID: 23892705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study.
    Oturai AB; Koch-Henriksen N; Petersen T; Jensen PE; Sellebjerg F; Sorensen PS
    Eur J Neurol; 2009 Mar; 16(3):420-3. PubMed ID: 19364368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).
    Clerico M; Schiavetti I; De Mercanti SF; Piazza F; Gned D; Brescia Morra V; Lanzillo R; Ghezzi A; Bianchi A; Salemi G; Realmuto S; Sola P; Vitetta F; Cavalla P; Paolicelli D; Trojano M; Sormani MP; Durelli L
    JAMA Neurol; 2014 Aug; 71(8):954-60. PubMed ID: 24977406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.
    Fox RJ; Cree BA; De Sèze J; Gold R; Hartung HP; Jeffery D; Kappos L; Kaufman M; Montalbán X; Weinstock-Guttman B; Anderson B; Natarajan A; Ticho B; Duda P;
    Neurology; 2014 Apr; 82(17):1491-8. PubMed ID: 24682966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Increased disease activity in a case of multiple sclerosis after switching treatment from fingolimod to natalizumab].
    Akatani R; Chihara N; Katanazaka K; Ueda T; Sekiguchi K; Matsumoto R
    Rinsho Shinkeigaku; 2019 Aug; 59(8):536-540. PubMed ID: 31341130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
    Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
    Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.